Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
story of the week
Published in Oncology

Journal Scan / Research · March 26, 2015

Vorinostat Did Not Improve Overall Survival in Advanced Malignant Pleural Mesothelioma

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

The Lancet Oncology
Vorinostat in Patients With Advanced Malignant Pleural Mesothelioma Who Have Progressed on Previous Chemotherapy (VANTAGE-014): A Phase 3, Double-Blind, Randomised, Placebo-Controlled Trial
Lancet Oncol 2015 Mar 19;[EPub Ahead of Print], LM Krug, HL Kindler, H Calvert, C Manegold, AS Tsao, D Fennell, R Öhman, R Plummer, WE Eberhardt, K Fukuoka, RM Gaafar, JJ Lafitte, G Hillerdal, Q Chu, WA Buikhuisen, GM Lubiniecki, X Sun, M Smith, P Baas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated